CN118159539A - 用于治疗亨廷顿氏病的杂芳基化合物 - Google Patents
用于治疗亨廷顿氏病的杂芳基化合物 Download PDFInfo
- Publication number
- CN118159539A CN118159539A CN202280066651.3A CN202280066651A CN118159539A CN 118159539 A CN118159539 A CN 118159539A CN 202280066651 A CN202280066651 A CN 202280066651A CN 118159539 A CN118159539 A CN 118159539A
- Authority
- CN
- China
- Prior art keywords
- pyrrolo
- pyridazin
- phenol
- triazol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 | |
| US63/203,761 | 2021-07-30 | ||
| PCT/US2022/038870 WO2023009816A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118159539A true CN118159539A (zh) | 2024-06-07 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280066651.3A Pending CN118159539A (zh) | 2021-07-30 | 2022-07-29 | 用于治疗亨廷顿氏病的杂芳基化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240336613A1 (enExample) |
| EP (1) | EP4377317A1 (enExample) |
| JP (1) | JP2024528066A (enExample) |
| KR (1) | KR20240054264A (enExample) |
| CN (1) | CN118159539A (enExample) |
| AR (1) | AR126612A1 (enExample) |
| AU (1) | AU2022320725A1 (enExample) |
| CA (1) | CA3227287A1 (enExample) |
| CL (1) | CL2024000250A1 (enExample) |
| CO (1) | CO2024000890A2 (enExample) |
| CR (1) | CR20240043A (enExample) |
| IL (1) | IL310440A (enExample) |
| MX (1) | MX2024001417A (enExample) |
| PE (1) | PE20240929A1 (enExample) |
| TW (1) | TW202321247A (enExample) |
| WO (1) | WO2023009816A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| CN119451674A (zh) * | 2022-06-15 | 2025-02-14 | Ptc医疗公司 | 用于治疗亨廷顿病的杂环和杂芳基化合物 |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) * | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227287A1 (en) | 2023-02-02 |
| TW202321247A (zh) | 2023-06-01 |
| KR20240054264A (ko) | 2024-04-25 |
| US20240336613A1 (en) | 2024-10-10 |
| CR20240043A (es) | 2024-05-22 |
| WO2023009816A1 (en) | 2023-02-02 |
| AR126612A1 (es) | 2023-10-25 |
| CL2024000250A1 (es) | 2024-07-12 |
| MX2024001417A (es) | 2024-05-14 |
| AU2022320725A1 (en) | 2024-02-22 |
| IL310440A (en) | 2024-03-01 |
| JP2024528066A (ja) | 2024-07-26 |
| CO2024000890A2 (es) | 2024-04-29 |
| PE20240929A1 (es) | 2024-04-30 |
| EP4377317A1 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12103926B2 (en) | Compounds for treating huntington's disease | |
| CN112654625B (zh) | 用于治疗亨廷顿氏病的杂环和杂芳基化合物 | |
| CN113717154B (zh) | 用于治疗亨廷顿病的方法 | |
| CN114245794B (zh) | 用于治疗亨廷顿氏病的化合物 | |
| CN111065626B (zh) | 用于治疗亨廷顿氏舞蹈病的化合物 | |
| KR20240054264A (ko) | Heteroaryl compounds for treating huntington's disease | |
| JP7799618B2 (ja) | ハンチントン病を処置するための化合物 | |
| CN119451674A (zh) | 用于治疗亨廷顿病的杂环和杂芳基化合物 | |
| EA051950B1 (ru) | Гетероарильные соединения для лечения болезни хантингтона | |
| HK40116823A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| EA041957B1 (ru) | Соединения для лечения болезни гентингтона | |
| NZ794019A (en) | Compounds for treating huntington's disease | |
| HK40043148A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| HK40043148B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |